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Summary A Phase 2 trial was conducted using intramuscular lymphoblastoid interferon (IFN, Wellcome
Research Laboratories), 4MU per day, in 10 patients with chemotherapy-resistant teratomas. There was
stabilisation of disease in 2 patients both of whom were in retrospect considered to have had differentiated
teratoma at the time of IFN administration. There was progression of presumed active anaplastic germ cell
tumour in 8 patients. One of these patients, a 15-year-old boy with biopsy proven differentiated teratoma has
received 2 courses of lymphoblastoid IFN and 1 course of recombinant leukocyte A IFN (Roche Products
Ltd.) lasting 52, 8 and 8+ months respectively. He has had a mixed response in his differentiated tumour
which on each occasion has been maintained for the duration that he received IFN. Rising HCG levels during
his second course of interferon required additional cytotoxic chemotherapy. Lymphoblastoid IFN does not
appear to be active against anaplastic germ cell tumours but both lymphoblastoid and recombinant leukocyte
A IFN may be useful in the treatment of unresectable differentiated teratoma.
Clinical trials of both lymphoblastoid and
recombinant leukocyte A IFN have demonstrated
objective responses in a variety of tumours (Toy,
1983; Sikora & Smedley, 1983). No in vitro or
clinical trial data have shown whether the growth
of germ cell tumours can be controlled by IFN. A
phase II clinical trial was therefore conducted to
determine the efficacy of lymphoblastoid IFN in
patients with cytotoxic drug-resistant anaplastic
(non-seminomatous) germ cell tumours as defined
by Paradinas (1983). Since it has been suggested
that IFN may be more effective against slow
growing rather than rapidly growing tumours (der
Bosch & Zirvi, 1982) it was administered to a
patient with unresectable differentiated teratoma.
When a partial response was seen attempts were
made to see if dose escalation enhanced the
response and whether the tumour was also
responsive to recombinant leukocyte A IFN.
Patients and methods
Lymphoblastoid IFN was given to 9 men and 1
woman who had residual tumour after receiving
intensive cytotoxic chemotherapy for metastatic
anaplastic germ cell tumours. All patients apart
from patient No. 7 had initially responded to
combination chemotherapy which included cis-
platinum in all cases and etoposide in all but one.
The residual tumour was considered active in 8
patients, because of rising AFP and/or HCG and
enlarging tumour masses in 5 (patients 5, 7, 8, 9
and 10, see Table), rising AFP alone in 2 (patients
1 and 4), and rising HCG in 1 (patient 6) (see
below). Two patients (2 and 3) who had been
treated with cytotoxic chemotherapy for active
anaplastic teratoma with elevated tumour marker
values were considered to have differentiated
teratoma at the time of IFN administration. Patient
No. 2 had slowly progressive left supraclavicular
and para aortic disease prior to IFN but with
undetectable tumour marker values. Following IFN
the supraclavicular mass responded completely to
radiotherapy but the para aortic mass after a
partial response to radiotherapy has slowly
increased in size over an 18 month period.
Computerized tomography (CT) scanning showed it
to be unresectable and partly cystic and its
behaviour was compatible with differentiated
teratoma. Patient No. 3 had gradually progressive
lung metastases but normal tumour marker values
for 12 months prior to IFN. He had a thoracotomy
after the metastases had been stable for 9 months
off IFN therapy when differentiated teratoma was
confirmed histologically. The patient (No. 6) whose
case history is below had differentiated teratoma
confirmed histologically on 4 occasions and was
considered to have active anaplastic germ cell
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TABLE I Details of teratoma patients
Response
Active or
differentiated
teratoma when
Patient Primary Weeks on IFN Markers
no. Age Histology Site IFN started Masses Pre Post
1 19 Yolk sac Ovary 4 Active 639 AFP 2000
2 39 MTI Testis 3 Differentiated SD
3 22 MTI Testis 4 Differentiated SD
4 36 MTU Testis 5 Active Uneval 857 AFP 1090
5 25 MTI Testis 4 Active PD 120 AFP 600
6 17 MTI Testis 86+ Differentiated MR 21 HCG 561
7 25 MTU Testis 2 Active PD 4722 AFP 7566
8 21 MTI Mediastinum 4 Active PD 4234 HCG 16590
9 25 MTI Testis 5 Active PD 3224 HCG 6235
1277 AFP 1389
10 33 * Mediastinum 4 Active PD 1180 AFP 2750
MTI=Malignant teratoma intermediate, MTU=Malignant teratoma undifferentiated, SD=Stable disease,
Uneval=Unevaluable, PD=Progressive disease, MR=Mixed response.
*Diagnosis presumed as mediastinal mass and AFP 64,000KU1 .
Age at start of IFN.
Units: HCG, IUI-1, AFP, KUl.
tumour with trophoblast when he had rising levels
of beta human chorionic gonadotrophin (HCG).
Lymphoblastoid IFN (Wellferon, supplied by
Wellcome Research Laboratories, Beckenham,
Kent) was given at a total dose of 4 Mega Units
(MU) daily intramuscularly for the periods shown
in Table I. It was started not less than 4 weeks
after the last course of cytotoxic chemotherapy.
Recombinant leukocyte A IFN (supplied by Roche
Products Ltd., Welwyn Garden City, U.K.) was
administered as described in the case history.
Results
There was progression of disease whilst on IFN as
judged by enlargement of evaluable tumour masses
and/or rising tumour markers in 8 of the 10
patients (patients 1 and 4-10) (Table I). In one of
these patients (case history below, patient No. 6) a
mixed response of his differentiated teratoma has
been obtained for 24+ months. There was
stabilization of evaluable masses in 2 patients (Nos.
2 and 3), who as previously discussed were later
considered to have differentiated teratoma. Patient
No. 2 had to stop IFN after only 3 weeks because
of a digital vasculitis (Sangster et al., 1983). Patient
No. 1 developed a septicaemia which responded to
antibiotics whilst on IFN. Toxicity was otherwise
similar to that previously reported with IFN
(Priestman, 1980; Scott et al., 1981) and included
fevers, rigors, malaise and myalgia. Although 6
patients developed some tolerance to the side effects
of IFN two patients found the side effects
intolerable.
Case History A 15-year-old post-pubertal boy (patient
No. 6) was found to have embryonal carcinoma with yolk
sac and teratomatous elements at orchidectomy in
November 1979. On starting chemotherapy on 28.11.79 he
was noted to have a 5cm diameter left supraclavicular
mass, a mediastinal mass, 3 lung metastases and a
palpable para aortic mass with a maximum diameter of
5cm on a CT scan, an HCG of 428IU/L and an alpha
foetoprotein of 9380KU -1 (Figure 1). He had 12 courses
of chemotherapy (POMB, ACE, OMB - Newlands et al.,
1983) over the next 7 months. Despite a satisfactory fall
in the tumour marker values the abdominal mass enlarged
but was unresectable at laparotomy on 2.5.80 and biopsy
confirmed that it consisted of differentiated teratoma.
Similar tissue was found when the enlarging left neck
mass was biopsied 22.10.80 and when a second
unsuccessful attempt was made at resecting the enlarging
abdominal mass on 5.6.81. There was further enlargement
of the mediastinal mass (Figure 1) through courses of
progesterone acetate 600mg daily for 12 weeks and
tamoxifen 40mg daily for 8 weeks. There was a rapid
partial response of the mediastinal and left supraclavicular
masses on starting lymphoblastoid IFN 4MU i.m. on
24.8.81. There was stabilization of these marker lesions
after 4 weeks when the dose was reduced to 4MU 3 times
weekly for 11 weeks but a further marginal response when
the dose was increased to 16MU per day. The
supraclavicular mass became almost impalpable, after two
5-day courses of IFN 170MU per day as infusion butIFN RESPONSE OF DIFFERENTIATED TERATOMA 613
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Figure 1 The surface area (CM2) of the mediastinal mass was assessed from chext X-ray as the product of the
two maximum perpendicular diameters using the left lateral border of the vertebral body as the medial edge
of the mass. C =cytoxic chemotherapy, P = Progesterone, T=Tamoxifen, E= Etretinate, Dotted
areas =Courses ofIFN, Vertical lines =High dose infusions of IFN, see text.
there was only slight further regression of the abominal
masses. There was a rapid regrowth of the measurable
lesions when the IFN was stopped and a 9 week course of
etretinate had no effect. However, there was a second
partial response when lymphoblastoid IFN was
reintroduced on 13.8.82. There was no additional response
with 3 further courses of high dose i.v. interferon. The left
supraclavicular mass was completely resected on 29.11.82
and consisted of differentiated teratoma. Electron
microscope studies were performed on this tissue (see
Figure 3). A venacavagram confirmed that the abdominal
masses were still unresectable. Serial CT scans showed
that they only decreased marginally in size during the
second 30 week course of IFN. This was stopped on
28.3.83 and 6 courses of cytotoxic chemotherapy
(EPOMB-ACE Bagshawe et al., 1983) started on 14.4.83
because the HCG had risen to 561IUl-l suggesting re-
growth of active anaplastic germ cell tumour. Despite
satisfactory fall in HCG levels the mediastinal and
abdominal masses enlarged during cytotoxic
chemotherapy such that he developed a left recurrent
laryngeal nerve palsy intermittent urinary retention and
swollen right leg. The last two problems have resolved
and have not recurred following intratumour injections of
14MU and 19.6MU lymphoblastoid IFN on 5.7.83 and
7.7.83 respectively and removal of 200ml of tumour cyst
fluid. On 1.8.83 the patient started on recombinant
leukocyte A IFN 6MU daily and increased to the
maintenance dose of 18MU alternate days on 31.10.83.
There was a further partial response in the mediastinal
mass (Figure 2) and marginal shrinkage of the abdominal
masses. He has administered the IFN himself and apart
from the expected toxicity (rigors, fever, malaise) during
the first two weeks of each course and when receiving the
high dose infusions (fever, severe malaise and
myelosuppression) experienced no side effects from either
preparation of IFN.
Electron microscopy
Part of the left supraclavicular node mass and buffy
coat from peripheral blood taken whilst patient No.
6 was receiving lymphoblastoid IFN were prepared
for electron microscopy as previously described
(Moss et al., 1982). Tubuloreticular structures were
found in peripheral blood lymphocytes and in
endothelial cells within the differentiated teratoma
mass (Figure 3). They were not seen in any other
cells.
Discussion
This study suggests that lymphoblastoid IFN has no
place in the treatment of cytotoxic drug-resistant
anaplastic germ cell tumours. With only 8 patients
with active anaplastic germ cell tumours in the
sample there was a probability of 0.05 that a
response rate of up to 35% was missed. In view of
the toxicity of the IFN in these heavily pre-treated
patients it was not considered ethical to continue
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Figure 2 Part ofchest X-ray before and 4 months after starting recombinant leukocyte A IFN.
Figure 3 Electron micrograph of endothelial cell within resected supraclavicular mass showing
tubuloreticular structures (arrowed).
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the trial with the aim of obtaining a more
statistically significant result. In the best centres,
combination chemotherapy can induce a long term
disease free state in over 80% of patients with
anaplastic germ cell tumours (Newlands et al.,
1983; Peckham et al., 1983; Vugrin & Golbey,
1983). Therefore only patients who have become
resistant to cytotoxic chemotherapy become eligible
for trials of new agents.
This study reports the first demonstration of IFN
inducing a response in differentiated (mature)
teratoma. This is a complex tumour composed of
somatic tissues derived from more than one germ
cell layer and resembles mature tissue (Paradinas,
1983). Elements of differentiated teratoma can be
found mixed with malignant elements in the
primary site of many patients with testicular germ
cell tumours. After completing cytotoxic
chemotherapy patients may have residual masses
many of which on surgical removal are found to be
composed of differentiated teratoma with no
immature elements (McCartney et al., 1984;
Peckham et al., 1983). It is unclear whether this is
due to selective killing by the chemotherapy of
immature elements or induction of differentiation.
Differentiated teratoma should be surgically
resected where possible because it can invade
locally and there is the potential for
dedifferentiation into more malignant tissue
(Loehrer et al., 1983). This was manifested in
patient No. 6 by a rising HCG concentration.
A response to a second course of IFN has
previously been reported in a patient with non
Hodgkin's lymphoma (Louie et al., 1981) but a
response to two different types of IFN has not been
previously reported. It is known that
lymphoblastoid IFN contains at least eight different
alpha sub-types and one of these is very similar to
the pure sub-type of the recombinant leukocyte A
IFN (Alan, 1982). To determine whether response
is sub-type specific would require the
administration of another purified sub-type.
No randomised studies have shown whether the
response rates to IFN are dose-dependent. However
there is a suggestion from non randomized studies
that higher response rates are seen with larger doses
of IFN than lower doses but at the expense of
greater toxicity. The mediastinal mass measurement
of J.B. indicated a marginal additional response on
dose escalation of lymphoblastoid IFN and the
effect of larger doses was even more pronounced on
the supraclavicular mass. However infusions of
170MU lymphoblastoid IFN daily for 5 days failed
to make the abdominal masses resectable.
It is unclear whether the action of the IFN on
the masses of differentiated teratoma were mediated
through an anti proliferative effect or through an
effect on one of the many cellular enzymes which
have been reported to be modulated by IFN
(Sreevalasan et al., 1981). Tubuloreticular structures
appear to be a footprint for high concentrations of
IFN and are seen in patients with systemic lupus
erythematosis and Kaposi's sarcoma (Rich et al.,
1983). As they were only seen in the endothelial
cells but not in the cystic teratoma cells of the
supraclavicular mass that responded to IFN they
do not appear to be a marker of response. Despite
the dramatic response of the supraclavicular mass
to IFN seen in patient No. 6, differentiated
teratoma was found in the resected tissue. This
tissue had previously been shown to be cystic on
ultrasound and it is possible that the decrease in the
size of the mass was solely due to resolution of the
cystic fluid. Nevertheless a reduction in the size of a
mass of differentiated teratoma in response to
interferon could make the difference in future
patients between a tumour being completely
resected or not.
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